Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 2/20 | 0.50 |
| ▸ | GALR3 | O60755 | 1/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.43 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25818192 | 0.88 | KDM4E (0.46) | AOC3GALR3HSP90AA1NR1H4MEN1 | |
| SCHEMBL2207386 | 0.88 | AOC3 (0.46) | AOC3GALR3HSP90AA1NR1H4TDP1 | |
| SCHEMBL29818907 | 0.88 | AOC3 (0.46) | AOC3GALR3HSP90AA1NR1H4TDP1 | |
| SCHEMBL25821909 | 0.86 | AOC3 (0.52) | AOC3L3MBTL1KDM4E | |
| SCHEMBL25821873 | 0.86 | AOC3 (0.52) | AOC3MEN1KMT2AL3MBTL1KDM4E | |
| SCHEMBL4568798 | 0.83 | TSHR (0.47) | AOC3GALR3HSP90AA1NR1H4MEN1 | |
| SCHEMBL19291383 | 0.82 | AOC3 (0.38) | AOC3GALR3HSP90AA1NR1H4 | |
| SCHEMBL25822195 | 0.82 | GALR3 (0.49) | GALR3HSP90AA1NR1H4MEN1KMT2A | |
| SCHEMBL25821996 | 0.80 | CACNA1B (0.47) | AOC3KDM4E | |
| SCHEMBL2206335 | 0.77 | NR1H4 (0.44) | AOC3GALR3HSP90AA1NR1H4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230218549-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230218549-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ALDH1A2, CLN6, AGER | AOC3 183/4885GALR3 101/4885HSP90AA1 2896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.